SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Eloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

Dosed first two patients in global Phase 2b EXACT study of exaluren in nonsense mutation Alport synd

ELOX

Related stories